WO1999032514A3 - Sag: gene sensible a l'apoptose - Google Patents

Sag: gene sensible a l'apoptose Download PDF

Info

Publication number
WO1999032514A3
WO1999032514A3 PCT/US1998/026705 US9826705W WO9932514A3 WO 1999032514 A3 WO1999032514 A3 WO 1999032514A3 US 9826705 W US9826705 W US 9826705W WO 9932514 A3 WO9932514 A3 WO 9932514A3
Authority
WO
WIPO (PCT)
Prior art keywords
sag
protein
sensitive
apoptosis
redox
Prior art date
Application number
PCT/US1998/026705
Other languages
English (en)
Other versions
WO1999032514A2 (fr
Inventor
Yi Sun
Original Assignee
Warner Lambert Co
Yi Sun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Yi Sun filed Critical Warner Lambert Co
Priority to AU19180/99A priority Critical patent/AU765741B2/en
Priority to JP2000525451A priority patent/JP2001526063A/ja
Priority to EP98963962A priority patent/EP1044217A2/fr
Priority to KR1020007006741A priority patent/KR20010033299A/ko
Priority to CA002303483A priority patent/CA2303483A1/fr
Priority to NZ503417A priority patent/NZ503417A/xx
Priority to BR9813757-3A priority patent/BR9813757A/pt
Publication of WO1999032514A2 publication Critical patent/WO1999032514A2/fr
Publication of WO1999032514A3 publication Critical patent/WO1999032514A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouveaux gènes et à des polypeptides dérivés de ces gènes codant une protéine sensible à l'oxydoréduction qui favorise la croissance cellulaire, protège les cellules contre l'apoptose, séquestre les radicaux d'oxygène et peut servir à inverser les phénotypes des tumeurs. Dans une tentative d'identifier un ou des gènes responsables de l'apoptose induite par 1,10-phénanthroline (OP) dans les cellules tumorales, nous avons utilisé la technique de présentation différentielle et cloné un gène induisible par OP, le SAG (gène sensible à l'apoptose). Le SAG code une nouvelle protéine sensible à l'oxydoréduction, se fixant à l'hème, à l'aide d'un domaine de protéines à doigt de zinc. La protéine de SAG se compose de 113 acides aminés, avec un poids moléculaire calculé de 12,7 kDa. Les recherches sur l'homologie des séquences ont révélé que le SAG est fortement conservé parmi les espèces, ce qui suggère son importance fonctionnelle. Cette suggestion est prouvée par la découverte selon laquelle la dislocation du SAG dans la levure est létale. Deux mutants de délétion du SAG ont été détectés dans des lignées cellulaires de cancer humain prenant naissance dans le colon et dans les testicules, ce qui suggère son possible rôle dans la carcinogenèse humaine. La surexpression de la protéine de SAG dans une lignée de carcinomes de colon humain, DLD1, et dans une lignée de neuroblastomes humains, SY5Y, protège les cellules contre l'apoptose induite par OP, par le zinc et par des ions de cuivre. En outre, la transfection de SAG anti-sens inhibe certains phénotypes de cellules tumorales dans les lignées de cellules humaines DLD1 et la micro-injection d'ARN de SAG stimule la croissance cellulaire. Nous proposons que la protéine de SAG soit une molécule de protection cellulaire fonctionnant comme un capteur d'oxydoréduction pour faire tampon aux dommages induits par des contraintes oxydatives, ainsi qu'un facteur de croissance destiné à stimuler la croissance cellulaire. La protéine de SAG peut être une cible moléculaire idéale dans l'élaboration de médicaments contre les maladies neurodégénératives, les cancers et les dystrophies musculaires, et pour favoriser la cicatrisation.
PCT/US1998/026705 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose WO1999032514A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU19180/99A AU765741B2 (en) 1997-12-19 1998-12-15 Sag: sensitive to apoptosis gene
JP2000525451A JP2001526063A (ja) 1997-12-19 1998-12-15 Ｓａｇ：アポトーシス感受性遺伝子
EP98963962A EP1044217A2 (fr) 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose
KR1020007006741A KR20010033299A (ko) 1997-12-19 1998-12-15 Ｓａｇ: 아팝토시스 감응성 유전자
CA002303483A CA2303483A1 (fr) 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose
NZ503417A NZ503417A (en) 1997-12-19 1998-12-15 Use of SAG (sensitive to apoptosis gene) in protecting cells from apoptosis
BR9813757-3A BR9813757A (pt) 1997-12-19 1998-12-15 Sag : sensìvel a gene de apoptose

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6817997P 1997-12-19 1997-12-19
US60/068,179 1997-12-19
US9984098P 1998-09-11 1998-09-11
US60/099,840 1998-09-11

Publications (2)

Publication Number Publication Date
WO1999032514A2 WO1999032514A2 (fr) 1999-07-01
WO1999032514A3 true WO1999032514A3 (fr) 1999-09-10

Family

ID=26748669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/026705 WO1999032514A2 (fr) 1997-12-19 1998-12-15 Sag: gene sensible a l'apoptose

Country Status (8)

Country Link
EP (1) EP1044217A2 (fr)
JP (1) JP2001526063A (fr)
KR (1) KR20010033299A (fr)
AU (1) AU765741B2 (fr)
BR (1) BR9813757A (fr)
CA (1) CA2303483A1 (fr)
NZ (1) NZ503417A (fr)
WO (1) WO1999032514A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078203B1 (en) 1999-03-31 2006-07-18 The University Of North Carolina At Chapel Hill Isolated DNA encoding cullin regulators ROC1 and ROC2, isolated proteins encoded by the same, and methods utilizing the same
WO2000058472A2 (fr) * 1999-03-31 2000-10-05 The University Of North Carolina At Chapel Hill Adn isole codant pour des regulateurs cullin roc1 et roc2, proteines isolees codees par ledit adn. procedes d'utilisation associes
WO2001046468A2 (fr) * 1999-12-21 2001-06-28 Eirx Therapeutics Ltd Technique de recherche
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6979551B2 (en) 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
EP1299558B1 (fr) * 2000-07-07 2006-05-10 Eirx Therapeutics Ltd Procede de criblage
IL156557A0 (en) * 2000-12-22 2004-01-04 Janssen Pharmaceutica Nv Bax-responsive genes for drug target identification in yeast and fungi
CN115345122B (zh) * 2022-08-31 2023-03-17 沐曦科技(北京)有限公司 一种用于仿真的非标准总线协议的芯片验证装置

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUAN H. ET AL.: "SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents", MOLECULAR AND CELLULAR BIOLOGY, vol. 19, no. 4, 1999, US, pages 3145 - 3155, XP002106009 *
HILLIER L. ET AL.: "Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 304814 5'", EMBL DATABASE, 17 May 1996 (1996-05-17), HEIDELBERG, DE, XP002106007 *
MARRA M. ET AL.: "Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone 401232 5'", EMBL DATABASE, 18 July 1996 (1996-07-18), HEIDELBERG, DE, XP002106008 *
SUN Y. ET AL.: "Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound", ONCOGENE, vol. 14, no. 4, 1997, pages 385 - 393, XP002106011 *
SUN Y.: "Induction of glutathione synthetase by 1,10-phenantroline", FEBS LETTERS, vol. 408, no. 1, 1997, AMSTERDAM NL, pages 16 - 20, XP002106010 *

Also Published As

Publication number Publication date
JP2001526063A (ja) 2001-12-18
CA2303483A1 (fr) 1999-07-01
KR20010033299A (ko) 2001-04-25
EP1044217A2 (fr) 2000-10-18
NZ503417A (en) 2002-12-20
BR9813757A (pt) 2000-10-03
WO1999032514A2 (fr) 1999-07-01
AU1918099A (en) 1999-07-12
AU765741B2 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
Macmillan-Crow et al. Manganese superoxide dismutase in disease
Kumar et al. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli
Chondrogianni et al. Proteasome dysfunction in mammalian aging: steps and factors involved
Mayeda et al. Two members of a conserved family of nuclear phosphoproteins are involved in pre-mRNA splicing.
WO1999032514A3 (fr) Sag: gene sensible a l'apoptose
MY181496A (en) Smoothened polypeptides and methods of use
EP1552298A4 (fr) Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
EP1340505A3 (fr) Utilisation thérapeutique de leurres d'éléments-cis in vivo
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
WO2001079556A3 (fr) Nouveaux genes, compositions et methodes destines a l'identification, l'evaluation, la prevention, et la therapie de cancers humains
Okinaga et al. Identification of a nuclear protein that constitutively recognizes the sequence containing a heat‐shock element: Its binding properties and possible function modulating heat‐shock induction of the rat heme oxygenase gene
Chondrogianni et al. Proteasome function determines cellular homeostasis and the rate of aging
Bataille Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?
CN103319605B (zh) 一种肝靶向肽与血管生成抑制因子融合蛋白及其制备方法与应用
WO2004064785A3 (fr) Sensibilisant d'une therapie de cancer
DE69110060D1 (de) In der humantherapie nützliche substanzen peptidischer natur.
WO2005089252B1 (fr) Methodes et compositions pour le traitement de l'obesite
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
WO2003092598A3 (fr) Traitement contre la maladie de pompe
Chao Damage-recognition proteins as a potential indicator of DNA-damage-mediated sensitivity or resistance of human cells to ultraviolet radiation
CN104480079A (zh) 一种发形霞水母超氧化物歧化酶及其编码基因与应用
Eberle et al. Human melanoma cell lines show little relationship between expression of pigmentation genes and pigmentary behaviour in vitro
WO2000079267A3 (fr) Traitement anticancereux
WO2002014369A3 (fr) Polypeptides du domaine d5 humain de production de kinine s
Kuschal et al. Cyclosporin A, but not everolimus, inhibits DNA repair in human fibroblasts and lymphoblasts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HR HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 19180/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2303483

Country of ref document: CA

Ref country code: CA

Ref document number: 2303483

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 503417

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09509779

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/003201

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998963962

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 525451

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1020007006741

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1998963962

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007006741

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020007006741

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998963962

Country of ref document: EP